Meeting Coverage

HRS

Heart Rhythm Society

Subcutaneous ICDs Take Care of Lead Complications in ATLAS Trial

But do they perform as well as standard transvenous ICDs?

HRS over a photo of Moscone Center South in San Francisco, CA

Latest HRS Meetings

Do Pediatric Electrophysiologists Have It Harder?

Clinicians discuss the dilemmas and shortcomings in the field

May 2, 2022
Menstrual Cycles Point to Link Between Sex Hormones and Long QT

Research suggests new tools for risk stratification and therapy

May 1, 2022
Minimally Invasive Procedure Shows Promise for Cutting Burden of Fainting Spells

U.S. registry-based study offers early results with cardioneural ablation in younger patients

May 1, 2022
CABANA Paints Afib Ablation as Cost 'Attractive'

Subanalysis results robustly inside willingness-to-pay thresholds

August 1, 2021
The Pill Can Spell Trouble for Long QTc

Cardiac events linked to one form in particular

July 31, 2021
Start Rhythm Control Early for Afib With Heart Failure

EAST-AFNET 4 trial finds similar benefits across ejection fraction ranges

July 31, 2021
Could Zapping the Spine Help Prevent Afib in High-Risk CABG Patients?

Pilot study yields dramatic results

July 30, 2021
LBB Pacing Linked to Better Outcomes in Comparative Study

Observational findings were promising

July 30, 2021
Cardiac Patch Monitors Don't Match Up on Detection

In simultaneous-use comparison, one device came out on top

July 30, 2021
DOAC Reduces Stroke Risk After Ventricular Ablation

Study treatment superior to aspirin, STROKE-VT trial shows

July 29, 2021
Pulsed Field Ablation Creeps Forward With Promising Early Studies

Success in pilot atrial fibrillation studies still leaves unanswered questions

May 13, 2020
Tool Pinpoints Cardiac Risk in Long QT Syndrome

Calculator is proposed to aid decisions on ICD appropriateness

May 11, 2020
Dissolving Pacemaker in the Works

Miniature, battery-free device has been promising in preclinical testing

May 11, 2020
Novel Nasal Spray Flops for Home Tachycardia Conversion

Phase III trial missed primary endpoint

May 8, 2020